4

PRIMARY DOCUMENT

Company: ALNYLAM PHARMACEUTICALS, INC.
Filed: April 28, 2023
Period of Report: April 26, 2023
Accession Number: 0001735276-23-000044

View Document ↗ View on SEC.gov ↗